FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

Cancer cell resistance arises when tyrosine kinase inhibitor (TKI)-targeted therapies induce a drug-tolerant persister (DTP) state with growth via genetic aberrations, making DTP cells potential therapeutic targets. We screened an anti-cancer compound library and identified fibroblast growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Furugaki, Koh, Fujimura, Takaaki, Mizuta, Hayato, Yoshimoto, Takuya, Asakawa, Takashi, Yoshimura, Yasushi, Yoshiura, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600219/
https://www.ncbi.nlm.nih.gov/pubmed/37880373
http://dx.doi.org/10.1038/s41698-023-00462-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600219/
https://www.ncbi.nlm.nih.gov/pubmed/37880373
http://dx.doi.org/10.1038/s41698-023-00462-0

Ejemplares similares